Arcturus Therapeutics Holdings (ARCT) Accounts Payables (2018 - 2026)

Arcturus Therapeutics Holdings (ARCT) has 9 years of Accounts Payables data on file, last reported at $4.1 million in Q1 2026.

• Quarterly Accounts Payables fell 33.76% year-over-year to $4.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.1 million (down 33.76% YoY) and the FY2025 annual result came in at $4.2 million, down 41.13% from the prior year.
• Accounts Payables retreated to $4.1 million in Q1 2026, from $4.2 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $19.3 million in Q1 2023 to a low of $4.1 million in Q1 2026.
• A 5-year average of $9.9 million and a median of $9.1 million in 2024 frame the typical range for Accounts Payables.
• Annual changes were most pronounced in 2023 — Accounts Payables jumped 136.36% — and 2024, when it sank 52.73%.
• Tracing ARCT's Accounts Payables over 5 years: stood at $7.4 million in 2022, then declined by 29.13% to $5.3 million in 2023, then surged by 36.28% to $7.2 million in 2024, then plunged by 41.13% to $4.2 million in 2025, then fell by 3.35% to $4.1 million in 2026.
• The last three Accounts Payables figures came in at $4.1 million (Q1 2026), $4.2 million (Q4 2025), and $5.5 million (Q3 2025), per Business Quant data.